The GASTHER-1 prospective study found that rescued HER2-positivity rate of 8.7% could be recognized with additional sampling among patients whose tumor was initially defined as HER2-negative, particularly among tumors with non-diffuse histology and HER2 2+ [165]. This evidence concerns the gene ERBB2 and neoplasm.